{"abstract":"This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to the current licensee, Lion Biotechnologies, Inc., which is located in Woodland Hills, California to practice the inventions embodied in the following patent applications and applications claiming priority to these applications: 1. U.S. Provisional Patent Application No. 61/237,889, filed August 26, 2009 entitled \"Adoptive cell therapy with young T cells\" (HHS Ref No. E-273-2009/0-US-01); 2. U.S. Patent No. 8,383,099 issued February 26, 2013 entitled \"Adoptive cell therapy with young T cells\" (HHS Ref No. E-273-2009/0- US-02); 3. U.S. Patent Application No. 13/742,541 filed January 16, 2013 entitled \"Adoptive cell therapy with young T cells\" (HHS Ref No. E- 273-2009/0-US-03); 4. U.S. Provisional Patent Application No. 61/466,200 filed March 22, 2011 entitled \"Methods of growing tumor infiltrating lymphocytes in gas-permeable containers\" (HHS Ref No. E-114-2011/0-US-01); 5. PCT Application No. PCT/US2012/029744 filed March 20, 2012 entitled \"Methods of growing tumor infiltrating lymphocytes in gas- permeable containers\" (HHS Ref No. E-114-2011/0-US-01); 6. U.S. Patent Application No. 13/424,646 filed May 20, 2012 entitled \"Methods of growing tumor infiltrating lymphocytes in gas- permeable containers\" (HHS Ref No. E-114-2011/0-US-01); 7. U.S. Provisional Patent Application No. 61/846,161 filed July 15, 2013 entitled \"Methods of Preparing Anti-human Papillomavirus Antigen T Cells\" (HHS Ref No. E-494-2013/0-US-01); 8. PCT Application No. PCT/US2014/046478 filed July 14, 2014 entitled \"Methods of Preparing Anti-human Papillomavirus Antigen T Cells\" (HHS Ref No. E-494-2013/0-PCT-02); The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to the use of the Licensed Patent Rights to develop, manufacture, distribute, sell and use unselected whole autologous tumor infiltrating lymphocyte (TIL) adoptive cell therapy products for the treatment of lung, breast, bladder, and HPV- positive cancers. Specifically excluded from this license are methods of generating or using selected subpopulations of TIL and the use of T cell receptors isolated from TIL.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2015/05/26/2015-12539.html","cfr_references":[],"citation":"80 FR 30080","comment_url":null,"comments_close_on":"2015-06-25","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 25, 2015 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2015-12539","effective_on":null,"end_page":30081,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2015/05/26/2015-12539.xml","html_url":"https://www.federalregister.gov/documents/2015/05/26/2015-12539/prospective-grant-of-exclusive-license-development-of-autologous-tumor-infiltrating-lymphocyte","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2015-12539?publication_date=2015-05-26","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2015-05-26/2015-12539/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":187,"last_updated":"2026-07-27 22:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2015-05-26/pdf/2015-12539.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2015-12539.pdf?1432298752","publication_date":"2015-05-26","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2015/05/26/2015-12539.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T03:24:54Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":30080,"subtype":null,"title":"Prospective Grant of Exclusive License: Development of Autologous Tumor Infiltrating Lymphocyte Adoptive Cells for the Treatment of Lung, Breast, Bladder, and HPV-Positive Cancers","toc_doc":"Development of Autologous Tumor Infiltrating Lymphocyte Adoptive Cells for the Treatment of Lung, Breast, Bladder, and HPV-Positive Cancers","toc_subject":"Exclusive Licenses:","topics":[],"type":"Notice","volume":80}